Plus Therapeutics, Inc. (PSTV)

US — Healthcare Sector
Peers: ADTX  PALI  REVB  QNRX  ZURA  CYTO  IMMX  ENVB  FWBI  DRMA  PBLA  CFRX  TARA  VCNX  MNPR  MIRO  SRZN  ATXI  HOTH  NRBO  VRAX 

Automate Your Wheel Strategy on PSTV

With Tiblio's Option Bot, you can configure your own wheel strategy including PSTV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PSTV
  • Rev/Share 0.5013
  • Book/Share -1.5177
  • PB -0.2423
  • Debt/Equity -0.3762
  • CurrentRatio 0.3382
  • ROIC 2.6326

 

  • MktCap 6250753.0
  • FreeCF/Share -1.9071
  • PFCF -0.5559
  • PE -0.1671
  • Debt/Assets 0.5076
  • DivYield 0
  • ROE 1.9527

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PSTV D. Boral Capital -- Buy -- $9 March 17, 2025

News

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
PSTV
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.

Read More
image for news Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
PSTV
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative

Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
PSTV
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference.

Read More
image for news Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
PSTV
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted.

Read More
image for news Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
PSTV
Published: March 11, 2025 by: Accesswire
Sentiment: Neutral

HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. "This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies," said Marc H.

Read More
image for news D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
PSTV
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive

The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.

Read More
image for news PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
PSTV
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H.

Read More
image for news Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

About Plus Therapeutics, Inc. (PSTV)

  • IPO Date 2001-07-11
  • Website https://www.plustherapeutics.com
  • Industry Biotechnology
  • CEO Dr. Marc H. Hedrick M.B.A., M.D.
  • Employees 21

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.